ReviewDigestive diseases and sciences2012
Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies.
Review in Digestive diseases and sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- KASL clinical practice guidelines: management of nonalcoholic fatty liver disease.Clinical and molecular hepatology · 2013Guideline
- Fenofibrate differentially activates PPARα-mediated lipid metabolism in rat kidney and liver.Scientific reports · 2025Article
- Review
- The effect ofFood science & nutrition · 2022Article
- Review
- Exploring the Gamut of Receptor Tyrosine Kinases for Their Promise in the Management of Non-Alcoholic Fatty Liver Disease.Biomedicines · 2021Review
- Effects of low and high doses of fenofibrate on protein, amino acid, and energy metabolism in rat.International journal of experimental pathology · 2020Article
- Ovary removal modifies liver message RNA profiles in single Comb White Leghorn chickens.Poultry science · 2020Article
- Activation of hepatic Nogo-B receptor expression-A new anti-liver steatosis mechanism of statins.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2018Article
- Amelioration of diet-induced steatohepatitis in mice following combined therapy with ASO-Fsp27 and fenofibrate.Journal of lipid research · 2017Article
- CIDEC/FSP27 is regulated by peroxisome proliferator-activated receptor alpha and plays a critical role in fasting- and diet-induced hepatosteatosis.Hepatology (Baltimore, Md.) · 2015Article
- Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.World journal of gastroenterology · 2014Review
- Perilipin-5 is regulated by statins and controls triglyceride contents in the hepatocyte.Journal of hepatology · 2014Article
- Role of diet and lifestyle changes in nonalcoholic fatty liver disease.World journal of gastroenterology · 2014Review
- Nonalcoholic fatty liver disease and cardiovascular disease.World journal of gastroenterology · 2014Review
- Synergistic interaction between genetics and disease on pravastatin disposition.Journal of hepatology · 2014Article
- Association between metabolic factors and chronic hepatitis B virus infection.World journal of gastroenterology · 2014Review
- Potential approaches to ameliorate hepatic fat accumulation seen with MTP inhibition.Drug safety · 2014Review
- Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.The Journal of pharmacology and experimental therapeutics · 2014Article
- Effects of rhaponticum carthamoides versus glycyrrhiza glabra and punica granatum extracts on metabolic syndrome signs in rats.BMC complementary and alternative medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease which refers to the presence of hepatic steatosis without significant intake of alcohol. NAFLD is an asymptomatic disease that can progress to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma. NAFLD is currently the most common cause of incidental abnormal liver tests and elevated serum liver enzyme activities in the developed world. Obesity, diabetes, and other components of the metabolic syndrome are frequently associated with the NAFLD. The treatment of NAFLD focuses on life-style modifications. Statins, fibrates, and other lipid-lowering agents have been proposed as effective lipid-lowering treatments in patients with NAFLD/NASH. However, clinicians are concerned that hyperlipidemic patients with NAFLD/NASH who are treated with statins could develop transaminitis. We assessed the efficacy and safety of lipid-lowering agents for NAFLD/NASH by reviewing reports of human studies including pilot, prospective, preliminary, and post hoc analysis studies on online databases during the period of 1980 to December 2012. The results of studies provide compelling evidence that lipid-lowering agents are safe and efficacious in patients with NAFLD/NASH and that some of these agents can induce a reduction in the extent of the hepatic steatosis. Well-designed randomized controlled studies of adequate size and duration with histological endpoints are needed in order to establish a suitable lipid-lowering treatment for hyperlipidemic patients with NAFLD/NASH, and for nonhyperlipidemic patients with NAFLD/NASH with a high risk for cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.